Want a Lifetime of Passive Income? Buy Altria Stock in July and Never Sell.

Altria (MO) is highlighted as a Dividend King with a 5.8% forward dividend yield versus the 10-Year Treasury’s 4.6%, and it used 81% of free cash flow to fund dividends over the past 12 months. The article argues dividend sustainability via smoke-free expansion (including NJOY acquired in 2023 and growing On! nicotine pouches), with a 2028 goal of at least $5B in smoke-free revenue (24% of projected sales). It also expects EPS growth at a 13% CAGR from 2025-2028 and values the stock at ~13x this year’s earnings, implying “dirt cheap” upside for long-term income investors.

Analysis

MO is best viewed as a high-yield cash-flow asset with a modest embedded regulatory call option, not a secular growth stock. That means the real driver is the spread between its dividend yield and risk-free rates: if rates stay sticky, the stock can remain range-bound even with stable fundamentals; if duration rallies, income buyers can re-rate the multiple quickly. The market is likely underappreciating how much of the upside is already being consumed by buybacks, so a clean EPS beat may not translate into a large rerating unless the yield spread widens.

The more interesting second-order effect is competitive consolidation inside nicotine alternatives. If regulators increase compliance costs or remove weaker players, the incumbents with distribution, legal budgets, and balance-sheet capacity should gain share even if category growth stays muted. That helps MO and PM more than it helps smaller vape/pouch brands, and it also raises the bar for new entrants to earn shelf space at retail.

Contrarian risk: “cheap” can be a trap if the business remains a slow-decline annuity. The bullish case depends on smoke-free mix improving faster than combustibles roll off; if that inflects lower, buybacks simply mask erosion and the stock becomes dead money with a dividend. Key falsifier over the next 1-3 quarters is any slowdown in guidance around smoke-free penetration or a deterioration in dividend coverage toward the high-80s of FCF.

Key Decisions for Investors

• Buy MO only on weakness or into a rate-driven pullback over the next 1-3 months; target is low-teens total return over 12 months from carry plus modest multiple support. Falsify if the stock re-rates above ~15x forward earnings without an upgrade to smoke-free growth.
• For income mandates, prefer selling 3-6 month cash-secured puts on MO rather than chasing spot; this monetizes the high yield while waiting for a better entry. Exit/avoid assignment if implied volatility collapses before any regulatory catalyst.
• Watch for an FDA tightening cycle that disproportionately hits smaller nicotine players; if that starts, the cleanest relative long is MO against the fragmented alternative-nicotine ecosystem rather than against PM. This is a 6-18 month share-consolidation trade, not a one-week momentum trade.
• Set a hard alert if smoke-free revenue guidance or mix trends disappoint in the next earnings cycle; that would invalidate the buyback-supported earnings story and likely cap upside despite the dividend.